What were the earnings and revenue surprises for Intellia Therapeutics (NTLA)?
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 8.20% and 44.39%, respectively, for the quarter ended June 2019.
What is Intellia Therapeutics Inc?
Intellia Therapeutics Inc is a genome editing company. It is focused on developing proprietary, potentially curative CRISPR/Cas9-based therapeutics. Its pipeline includes in vivo development programs targeting genetic diseases, including transthyretin amyloidosis and hereditary angioedema, and ex vivo programs which include Acute Myeloid Leukemia.
Can Intellia (NTLA) prevent heart attacks in hereditary angioedema?
Intellia (NTLA) doses the first patient in a phase I/II study to evaluate NTLA-2002 as a single-dose therapy for preventing attacks in patients having hereditary angioedema.
Is Intellia a publicly traded company?
Intellia's stock is traded on the NASDAQ Global Market under the symbol NTLA. The company's initial public offering (IPO) was in May 2016.
Is Intellia Therapeutics a buy?
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Intellia Therapeutics Inc stock to perform well in the short-term.
Is NTLA a good stock?
Out of 12 analysts, 4 (33.33%) are recommending NTLA as a Strong Buy, 7 (58.33%) are recommending NTLA as a Buy, 1 (8.33%) are recommending NTLA as a Hold, 0 (0%) are recommending NTLA as a Sell, and 0 (0%) are recommending NTLA as a Strong Sell.
Why is Intellia Therapeutics stock dropping?
Intellia's (NTLA) shares decline following the decision of the USPTO, invalidating the patents licensed by Intellia to develop CRISPR-based gene therapies.
How high can NTLA go?
Intellia Therapeutics Inc (NASDAQ:NTLA) The 22 analysts offering 12-month price forecasts for Intellia Therapeutics Inc have a median target of 125.00, with a high estimate of 207.00 and a low estimate of 54.00. The median estimate represents a +83.39% increase from the last price of 68.16.
Why is Intellia down?
Intellia stock has plunged since the trademark office decided not to grant patents the company had relied on.
Will NTLA keep going up?
Based on our forecasts, a long-term increase is expected, the "NTLA" stock price prognosis for 2027-07-16 is 237.779 USD. With a 5-year investment, the revenue is expected to be around +264.75%. Your current $100 investment may be up to $364.75 in 2027. Get It Now!
What is NTLA target price?
Stock Price Target NTLAHigh$207.00Median$125.00Low$54.00Average$128.68Current Price$65.47
Does Intellia stock pay dividends?
Intellia Therapeutics (NASDAQ: NTLA) does not pay a dividend.
How many patents does Intellia therapeutics have?
26 patentsIntellia Therapeutics has filed 26 patents. The 3 most popular patent topics include: Molecular biology. Biotechnology.
What is Crispr stock price?
$83.39$ 83.39CloseChgChg %$83.391.481.81%
Why is Editas stock down?
However, the main factor behind Editas' decline this week appears to be the overall sell-off in biotech stocks.
Market check: Stocks mixed at open as volatility spikes
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q4 Earnings Expected to Decline
Yahoo Finance's Jared Blikre breaks down how markets opened on Friday.
The Petri Dish: 2seventy rounds out C-suite, Moderna goes global
Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intellia (NTLA) Up on Deal With ONK for Cancer Therapies
The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of health care happenings.
Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer
Intellia (NTLA) partners with ONK Therapeutics. The collaboration utilises their respective proprietary platforms to develop allogeneic CRISPR-based NK cell therapies for the treatment of cancer.
Newsflash: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Analysts Have Been Trimming Their Revenue Forecasts
Collaboration combines Intellia’s genome editing platform with ONK’s optimized natural killer (NK) cell therapy platform Intellia grants ONK non-exclusive rights to its ex vivo genome editing and LNP delivery technologies and exclusive rights to certain guide RNAs for up to five allogeneic CRISPR-edited NK cell therapies ONK is responsible for the research, clinical development and commercialization of engineered NK cell therapies derived from collaboration Intellia to receive global co-developm.
What is Intellia Therapeutics?
The latest analyst coverage could presage a bad day for Intellia Therapeutics, Inc. ( NASDAQ:NTLA ), with the analysts...
Where is Intellia Therapeutics located?
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
What is NTLA 2001?
in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Who is the head of quantitative research at Morningstar?
The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.
What is Morningstar quantitative rating?
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here .
What is transparency in investing?
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
How many articles has the Fool written on Intellia Therapeutics?
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
Did Intelllia give back its gains?
The Fool has written over 100 articles on Intellia Therapeutics.
